Thursday May 25th 2017

Archive for May, 2010

Manitoban travels to Egypt for controversial treatment

Manitoban travels to Egypt for controversial treatment

A Manitoba woman has gone half-way around the world for a controversial therapy for her multiple sclerosis. Nicole Benes travelled to Egypt to undergo a treatment for a condition known CCSVI, or chronic cerebro-spinal venous insufficiency, that a doctor has associated with [Read More]

Treatment liberating for MS sufferer

Treatment liberating for MS sufferer

Chris Alkenbrack walked down the driveway, a leash in one hand and a neon green cane in the other. A tiny pug dog at the end of the leash jumped up in friendly fashion to greet a visitor. Alkenbrack was just back from a walk along the quiet roads of Forest Hill, a hamlet [Read More]

Saskatchewan Woman Says MS Operation “Did Wonders”

Saskatchewan Woman Says MS Operation “Did Wonders”

A Rosetown, Sask., woman says she feels “150 per cent better” after receiving a much publicized, but controversial, treatment for her multiple sclerosis. “I’m a different person today than I was four weeks ago,” said Val Hoenecke, a math [Read More]

 Page 1 of 15  1  2  3  4  5 » ...  Last » 

Latest Topics

MS Study Alert: Share Your Thoughts About MS Research

MS Study Alert: Share Your Thoughts About MS Research

/About-the-Society/News/MS-Study-Alert-Share-Your-Thoughts-About-MS-Resea [Read More]

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

UK-based specialist pharmaceutical firm Mallinckrodt has begun patient enrolment in the Phase IV OPTIONS clinical trial [Read More]

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

/About-the-Society/News/First-Results-Announced-from-Second-Phase-III-Tria [Read More]

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Immune diseases like multiple sclerosis and hemophagocytic lymphohistiocytosis unleash destructive waves of [Read More]

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

US-based biopharmaceutical firm Celgene has reported positive results from the Phase III RADIANCE clinical trial of [Read More]